Literature DB >> 8077720

Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.

A K Bhattacharjee1, S M Opal, J E Palardy, J J Drabick, H Collins, R Taylor, A Cotton, A S Cross.   

Abstract

Antibodies were raised in rabbits by immunization with the heat-killed J5 mutant of Escherichia coli O111 (Rc chemotype). Serum antibodies were separated into purified IgG and IgM by sequential affinity chromatography on protein G-Sepharose and anti-rabbit IgG-Sepharose columns. J5 lipopolysaccharide (LPS)-specific IgG was prepared by affinity chromatography of purified IgG on a J5 LPS-EAH Sepharose 4B affinity column. Purified IgM, IgG, and J5 LPS-specific IgG protected neutropenic rats against lethal challenge with Pseudomonas aeruginosa 12:4:4 (Fisher Devlin immunotype 6). Nine of 16 rats treated with the IgM fraction were protected (P < .001). Thirteen of 20 rats treated with the purified IgG and 6 of 8 treated with J5 LPS-specific IgG were protected compared with none of 25 treated with IgG made from the preimmune serum of the same rabbit (P < .001). These results demonstrate that purified J5 LPS-specific IgG protects against the lethal consequences of gram-negative bacteremia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077720     DOI: 10.1093/infdis/170.3.622

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Preparation of immunoglobulin Y (IgY) against lipopolysaccharide using gel chromatography from the yolks of eggs laid by immunized hens.

Authors:  Siyuan Ma; Yaping Zhang
Journal:  Protein J       Date:  2010-10       Impact factor: 2.371

2.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

Review 3.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

4.  Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

5.  Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent.

Authors:  J J Drabick; A K Bhattacharjee; D L Hoover; G E Siber; V E Morales; L D Young; S L Brown; A S Cross
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Impaired control of Brucella melitensis infection in Rag1-deficient mice.

Authors:  M J Izadjoo; Y Polotsky; M G Mense; A K Bhattacharjee; C M Paranavitana; T L Hadfield; D L Hoover
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

7.  Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors.

Authors:  Wilbur H Chen; Subhendu Basu; Apurba K Bhattacharjee; Alan S Cross
Journal:  Innate Immun       Date:  2009-10-12       Impact factor: 2.680

8.  A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsis.

Authors:  Alan S Cross; Steven M Opal; John E Palardy; Surekha Shridhar; Scott M Baliban; Alison J Scott; Abdullah B Chahin; Robert K Ernst
Journal:  Innate Immun       Date:  2021-04       Impact factor: 2.680

Review 9.  Review: the role of GSDMD in sepsis.

Authors:  Ruifei Shao; Xiran Lou; Jinfang Xue; Deyuan Ning; Guobing Chen; Lihong Jiang
Journal:  Inflamm Res       Date:  2022-08-15       Impact factor: 6.986

Review 10.  Anti-endotoxin vaccines: back to the future.

Authors:  Alan S Cross
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.